Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Loss of FAT Atypical Cadherin 4 Expression Is Associated with High Pathologic T Stage in Radically Resected Gastric Cancer

  • Jung, Hae Yoen (Department of Pathology, Soonchunhyang University Cheonan Hospital) ;
  • Cho, Hyundeuk (Department of Pathology, Soonchunhyang University College of Medicine) ;
  • Oh, Mee-Hye (Department of Pathology, Soonchunhyang University Cheonan Hospital) ;
  • Lee, Ji-Hye (Department of Pathology, Soonchunhyang University Cheonan Hospital) ;
  • Lee, Hyun Ju (Department of Pathology, Soonchunhyang University Cheonan Hospital) ;
  • Jang, Si-Hyong (Department of Pathology, Soonchunhyang University Cheonan Hospital) ;
  • Lee, Moon Soo (Department of Surgery, Soonchunhyang University Cheonan Hospital)
  • Received : 2015.01.19
  • Accepted : 2015.02.08
  • Published : 2015.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Recent studies have revealed recurrent alterations in the cell adhesion gene FAT4, a candidate tumor suppressor gene, in cancer. FAT atypical cadherin 4 (FAT4) is a transmembrane receptor involved in the Hippo signaling pathway, which is involved in the control of organ size. Here, we investigated the loss of FAT4 expression and its association with clinicopathological risk factors in gastric cancer. Materials and Methods: We assessed the expression of FAT4 by using immunohistochemistry on three tissue microarrays containing samples from 136 gastric cancer cases, radically resected in the Soonchunhyang University Cheonan Hospital between July 2006 and June 2008. Cytoplasmic immunoexpression of FAT4 was semi-quantitatively scored using the H-score system. An H-score of ${\geq}10$ was considered positive for FAT4 expression. Results: Variable cytoplasmic expressions of FAT4 were observed in gastric cancers, with 33 cases (24.3%) showing loss of expression (H-score <10). Loss of FAT4 expression was associated with an increased rate of perineural invasion (H-score <10 vs. ${\geq}10$, 36.4% vs. 16.5%, P=0.015), high pathologic T stage (P=0.015), high tumor-node-metastasis stage (P=0.017), and reduced disease-free survival time (H-score <10 vs. ${\geq}10$, mean survival $62.7{\pm}7.3$ months vs. $79.1{\pm}3.1$ months, P=0.025). However, no association was found between the loss of FAT4 expression and tumor size, gross type, histologic subtype, Lauren classification, lymphovascular invasion, or overall survival. Conclusions: Loss of FAT4 expression appears to be associated with invasiveness in gastric cancer.

Keywords

References

  1. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol 2009;472:467-477. https://doi.org/10.1007/978-1-60327-492-0_23
  2. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012;44:570-574. https://doi.org/10.1038/ng.2246
  3. Bryant PJ, Huettner B, Held LI Jr, Ryerse J, Szidonya J. Mutations at the fat locus interfere with cell proliferation control and epithelial morphogenesis in Drosophila. Dev Biol 1988;129:541-554. https://doi.org/10.1016/0012-1606(88)90399-5
  4. Axelrod JD. Progress and challenges in understanding planar cell polarity signaling. Semin Cell Dev Biol 2009;20:964-971. https://doi.org/10.1016/j.semcdb.2009.08.001
  5. Willecke M, Hamaratoglu F, Kango-Singh M, Udan R, Chen CL, Tao C, et al. The fat cadherin acts through the hippo tumor-suppressor pathway to regulate tissue size. Curr Biol 2006;16:2090-2100. https://doi.org/10.1016/j.cub.2006.09.005
  6. Katoh M. Function and cancer genomics of FAT family genes (review). Int J Oncol 2012;41:1913-1918. https://doi.org/10.3892/ijo.2012.1669
  7. Conlon I, Raff M. Size control in animal development. Cell 1999;96:235-244. https://doi.org/10.1016/S0092-8674(00)80563-2
  8. Johnston LA, Gallant P. Control of growth and organ size in Drosophila. Bioessays 2002;24:54-64. https://doi.org/10.1002/bies.10021
  9. Valletta D, Czech B, Thasler WE, Muller M, Bosserhoff AK, Hellerbrand C. Expression and function of the atypical cadherin FAT1 in chronic liver disease. Biochem Biophys Res Commun 2012;426:404-408. https://doi.org/10.1016/j.bbrc.2012.08.104
  10. Edgar BA. From cell structure to transcription: Hippo forges a new path. Cell 2006;124:267-273. https://doi.org/10.1016/j.cell.2006.01.005
  11. Sadeqzadeh E, de Bock CE, Thorne RF. Sleeping giants: emerging roles for the fat cadherins in health and disease. Med Res Rev 2014;34:190-221. https://doi.org/10.1002/med.21286
  12. Qi C, Zhu YT, Hu L, Zhu YJ. Identification of Fat4 as a candidate tumor suppressor gene in breast cancers. Int J Cancer 2009;124:793-798. https://doi.org/10.1002/ijc.23775
  13. Rauch TA, Wang Z, Wu X, Kernstine KH, Riggs AD, Pfeifer GP. DNA methylation biomarkers for lung cancer. Tumour Biol 2012;33:287-296. https://doi.org/10.1007/s13277-011-0282-2
  14. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-1117. https://doi.org/10.1038/nature09515

Cited by

  1. History and progression of Fat cadherins in health and disease vol.9, pp.None, 2015, https://doi.org/10.2147/ott.s111176
  2. FAT4 hypermethylation and grade dependent downregulation in gastric adenocarcinoma vol.11, pp.1, 2015, https://doi.org/10.1007/s12079-016-0355-5
  3. Identification of genomic aberrations associated with lymph node metastasis in diffuse-type gastric cancer vol.50, pp.4, 2015, https://doi.org/10.1038/s12276-017-0009-6